VivoSeq
Oncology

Metastatic Breast Cancer (MBC)

2

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Metastatic Breast Cancer (MBC) is an early-stage landscape with 2 programs across 1 company. The most active players are Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical2

Palbociclib

Pfizer

Bicalutamide

Istituto Clinico Humanitas

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Not yet recruiting1 · 50%
Active, not recruiting1 · 50%

Clinical Trials

Trial Activity

Evaluating a Patient Navigation Program to Improve Therapy Management for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib
Not yet recruiting·DDuke University·Preclinical·NCT06983691·26 enrolled
Phase I/II Trial of Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT02605486·46 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)